Pharmacological, psychosocial, and brain stimulation interventions in oncologic populations with mental disorders: An umbrella review.

Psychiatry ResMay 16, 2026 (epub)

Michele Fornaro, Chiara Di Lorenzo, Domenico De Berardis et al.

✦ AI-curated · Sources linked

In 30 seconds

This umbrella review analyzed 82 meta-analyses of randomized controlled trials assessing pharmacological, psychosocial, and brain stimulation interventions for mental disorders in cancer patients. The review found that mindfulness-based stress reduction significantly outperformed standard treatment for anxiety in lung cancer, with a Hedges' g of -1.46. Most studies focused on major depressive and anxiety disorders.

Key findings

  • Mindfulness-based stress reduction significantly outperformed standard treatment for anxiety in lung cancer (Hedges' g=-1.46).
  • Psychotherapy for women post-mastectomy was inferior to waiting list in treating anxiety (G=0.33).
  • 48.67% of studies focused on major depressive disorders among oncologic populations.
  • Meta-regression indicated psychotherapies may benefit females more than males.

Why it matters

Understanding the efficacy of various interventions for mental health disorders in cancer patients is crucial for improving patient care. This review highlights the need for effective treatment strategies tailored to this population, particularly for anxiety and depression.

Source

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.